Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

2 Under-the-Radar Biotech Stocks to Buy in 2022

TheMotleyFool

0 0

2 Under-the-Radar Biotech Stocks to Buy in 2022

Whenever a small drugmaker fails to earn approval for a new product, its shares are likely to drop. But these regulatory headwinds can sometimes create excellent buying opportunities in the volatile biotech industry, provided the company in question can address regulators' concerns and eventually receive the green light for its product.

Many companies find themselves in this very situation as we speak. Two in particular look promising: Axsome Therapeutics (NASDAQ: AXSM) and Provention Bio (NASDAQ: PRVB). These aren't the most prominent biotechs, and their shares look somewhat risky. But there are good reasons to consider initiating positions in both.